The use of darbepoetin in infants with chronic renal impairment

Area of Science:

• Pediatric Nephrology
• Pharmacology

Background:

• Erythropoietin stimulating agents (ESAs) are crucial for managing anemia in chronic kidney disease (CKD).
• Darbepoetin alfa, a longer-acting ESA, offers potential for less frequent administration compared to traditional erythropoietin.
• Limited data exists on darbepoetin alfa use in the infant population.

Purpose of the Study:

• To evaluate the safety and efficacy of darbepoetin alfa in infants weighing less than 8 kg with chronic renal impairment.
• To determine appropriate dosing strategies and assess treatment outcomes in this vulnerable population.

Main Methods:

• Retrospective case series of six infants with chronic renal impairment.
• Darbepoetin alfa initiated at approximately 0.5 microg/kg/week, with iron studies monitored regularly.
• Dose adjustments and iron supplementation were guided by hemoglobin, ferritin, and transferrin saturation levels.

Main Results:

• Three stable infants achieved target hemoglobin levels with reduced darbepoetin alfa doses (0.25 microg/kg/week) and extended dosing intervals (every 3-4 weeks).
• Three medically unstable infants, requiring hemodialysis and surgery, did not reach target hemoglobin despite increased doses (up to 1.2 microg/kg/week).
• Individualized dosing and iron supplementation appear critical for treatment success.

Conclusions:

• Darbepoetin alfa can be administered to infants with chronic renal insufficiency.
• Treatment efficacy is dependent on individual patient stability and requires tailored dosing.
• Smaller, single-dose syringes could improve administration convenience.